LJPC 501

Drug Profile

LJPC 501

Alternative Names: LJPC-501; Synthetic angiotensin II - La Jolla

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin receptor agonists; Sodium-hydrogen antiporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypotension
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 02 Aug 2016 Phase-III clinical trials in Hypotension in Germany (IV) (EudraCT2015-002448-15)
  • 09 Mar 2016 Phase-III clinical trials in Hypotension in Canada and Finland (IV)
  • 30 Nov 2015 LaJolla Pharmaceutical receives patent allowance for LJPC-501 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top